Tag: Gene Therapy Reimbursement Models
2024 Guide to FDA-Approved CRISPR Rare Disease Gene Therapy Innovations: Regulatory Pathways, Orphan Drug Development Economics, and Reimbursement Models
Per October 2024 FDA, National Organization for Rare Disorders (NORD), and Tufts Center for the Study of Drug Development data, this 2024 FDA-approved CRISPR rare disease gene therapy buying guide breaks down 5 key 2024 regulatory updates, orphan drug development economics, and reimbursement models for patients and biotech teams. We compare premium FDA-validated CRISPR therapy